Abstract
Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multiple biological processes has gained lots of attention. There is increasing interest in HDAC6 and its selective inhibitors. More than twenty years of synthetic efforts have developed various HDAC6 selective inhibitors with different Cap, linker and ZBG. This review will summarize recent research data regarding HDAC6 and various HDAC6 selective inhibitors.
Keywords: Epigenetics, HDAC6, Protein degradation, Neurodegenerative disease, Cancer, HDAC6 selective inhibitors.
Current Topics in Medicinal Chemistry
Title:Structure, Functions and Selective Inhibitors of HDAC6
Volume: 18 Issue: 28
Author(s): Tao Liang and Hao Fang*
Affiliation:
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
Keywords: Epigenetics, HDAC6, Protein degradation, Neurodegenerative disease, Cancer, HDAC6 selective inhibitors.
Abstract: Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multiple biological processes has gained lots of attention. There is increasing interest in HDAC6 and its selective inhibitors. More than twenty years of synthetic efforts have developed various HDAC6 selective inhibitors with different Cap, linker and ZBG. This review will summarize recent research data regarding HDAC6 and various HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Liang Tao and Fang Hao *, Structure, Functions and Selective Inhibitors of HDAC6, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181129141822
DOI https://dx.doi.org/10.2174/1568026619666181129141822 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems
Current Topics in Medicinal Chemistry Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate
Current Drug Delivery Mechanisms and Consequences of Protein Aggregation: The Role of Folding Intermediates
Current Protein & Peptide Science Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials New and Emerging Antiresorptive Treatments in Osteoporosis
Current Drug Safety Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets